A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation

Robert J. Fontana, Hie Won L Hann, Teresa Wright, Gregory Everson, Alfred Baker, Eugene R Schiff, Carolyn Riely, Gaya Anschuetz, Melanie Riker-Hopkins, Nathaniel Brown

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) infection after liver transplantation (LT) may lead to severe and rapidly progressive graft failure. Antiviral treatment may be of benefit in selected patients with recurrent hepatitis B post-LT. The aim of this prospective open-label study is to determine the safety and efficacy of lamivudine in 33 liver transplant recipients with active HBV infection. The median time from LT to study enrollment was 51 months, all patients were hepatitis B surface antigen positive, and 75% and 94% of subjects had detectable hepatitis B e antigen (HBeAG) and HBV DNA at entry, respectively. The median duration of lamivudine treatment on study was 85 weeks, during which time median HBV DNA levels became undetectable by 16 weeks and 9% of patients lost previously detectable HBeAg. Serum alanine aminotransferase (ALT) levels improved in most patients and normalized in 27% of patients with elevated values pretreatment. Serum bilirubin and albumin levels significantly improved in patients with abnormal values at entry (P < .05). Virological breakthrough was detected in 13 subjects after a median of 61 weeks of lamivudine treatment and was confirmed to be caused by YMDD mutants in all patients tested. None of the patients with virological breakthrough showed a complete loss of clinical response to lamivudine. Serum ALT and bilirubin levels in patients with and without virological breakthrough were not significantly different at last study follow-up. Study results show that lamivudine is safe and effective in liver transplant recipients with recurrent hepatitis B. However, the high rate of virological breakthrough with prolonged therapy indicates the need for further studies of combination antiviral therapy in this patient population. Our results and others further establish the improving long-term outcomes with LT for patients with hepatitis B through advances in prevention of reinfection, as well as the availability of safe and effective antiviral therapies to treat patients with HBV recurrence.

Original languageEnglish
Pages (from-to)504-510
Number of pages7
JournalLiver Transplantation
Volume7
Issue number6
DOIs
StatePublished - Jun 28 2001

Fingerprint

Lamivudine
Hepatitis B
Liver Transplantation
Multicenter Studies
Hepatitis B virus
Therapeutics
Antiviral Agents
Hepatitis B e Antigens
Virus Diseases
Alanine Transaminase
Bilirubin
Liver
DNA
Hepatitis B Surface Antigens
Serum
Serum Albumin

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. / Fontana, Robert J.; Hann, Hie Won L; Wright, Teresa; Everson, Gregory; Baker, Alfred; Schiff, Eugene R; Riely, Carolyn; Anschuetz, Gaya; Riker-Hopkins, Melanie; Brown, Nathaniel.

In: Liver Transplantation, Vol. 7, No. 6, 28.06.2001, p. 504-510.

Research output: Contribution to journalArticle

Fontana, RJ, Hann, HWL, Wright, T, Everson, G, Baker, A, Schiff, ER, Riely, C, Anschuetz, G, Riker-Hopkins, M & Brown, N 2001, 'A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation', Liver Transplantation, vol. 7, no. 6, pp. 504-510. https://doi.org/10.1053/jlts.2001.24896
Fontana, Robert J. ; Hann, Hie Won L ; Wright, Teresa ; Everson, Gregory ; Baker, Alfred ; Schiff, Eugene R ; Riely, Carolyn ; Anschuetz, Gaya ; Riker-Hopkins, Melanie ; Brown, Nathaniel. / A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. In: Liver Transplantation. 2001 ; Vol. 7, No. 6. pp. 504-510.
@article{65d95633936042a49aa99d5e74cd386b,
title = "A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation",
abstract = "Hepatitis B virus (HBV) infection after liver transplantation (LT) may lead to severe and rapidly progressive graft failure. Antiviral treatment may be of benefit in selected patients with recurrent hepatitis B post-LT. The aim of this prospective open-label study is to determine the safety and efficacy of lamivudine in 33 liver transplant recipients with active HBV infection. The median time from LT to study enrollment was 51 months, all patients were hepatitis B surface antigen positive, and 75{\%} and 94{\%} of subjects had detectable hepatitis B e antigen (HBeAG) and HBV DNA at entry, respectively. The median duration of lamivudine treatment on study was 85 weeks, during which time median HBV DNA levels became undetectable by 16 weeks and 9{\%} of patients lost previously detectable HBeAg. Serum alanine aminotransferase (ALT) levels improved in most patients and normalized in 27{\%} of patients with elevated values pretreatment. Serum bilirubin and albumin levels significantly improved in patients with abnormal values at entry (P < .05). Virological breakthrough was detected in 13 subjects after a median of 61 weeks of lamivudine treatment and was confirmed to be caused by YMDD mutants in all patients tested. None of the patients with virological breakthrough showed a complete loss of clinical response to lamivudine. Serum ALT and bilirubin levels in patients with and without virological breakthrough were not significantly different at last study follow-up. Study results show that lamivudine is safe and effective in liver transplant recipients with recurrent hepatitis B. However, the high rate of virological breakthrough with prolonged therapy indicates the need for further studies of combination antiviral therapy in this patient population. Our results and others further establish the improving long-term outcomes with LT for patients with hepatitis B through advances in prevention of reinfection, as well as the availability of safe and effective antiviral therapies to treat patients with HBV recurrence.",
author = "Fontana, {Robert J.} and Hann, {Hie Won L} and Teresa Wright and Gregory Everson and Alfred Baker and Schiff, {Eugene R} and Carolyn Riely and Gaya Anschuetz and Melanie Riker-Hopkins and Nathaniel Brown",
year = "2001",
month = "6",
day = "28",
doi = "10.1053/jlts.2001.24896",
language = "English",
volume = "7",
pages = "504--510",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation

AU - Fontana, Robert J.

AU - Hann, Hie Won L

AU - Wright, Teresa

AU - Everson, Gregory

AU - Baker, Alfred

AU - Schiff, Eugene R

AU - Riely, Carolyn

AU - Anschuetz, Gaya

AU - Riker-Hopkins, Melanie

AU - Brown, Nathaniel

PY - 2001/6/28

Y1 - 2001/6/28

N2 - Hepatitis B virus (HBV) infection after liver transplantation (LT) may lead to severe and rapidly progressive graft failure. Antiviral treatment may be of benefit in selected patients with recurrent hepatitis B post-LT. The aim of this prospective open-label study is to determine the safety and efficacy of lamivudine in 33 liver transplant recipients with active HBV infection. The median time from LT to study enrollment was 51 months, all patients were hepatitis B surface antigen positive, and 75% and 94% of subjects had detectable hepatitis B e antigen (HBeAG) and HBV DNA at entry, respectively. The median duration of lamivudine treatment on study was 85 weeks, during which time median HBV DNA levels became undetectable by 16 weeks and 9% of patients lost previously detectable HBeAg. Serum alanine aminotransferase (ALT) levels improved in most patients and normalized in 27% of patients with elevated values pretreatment. Serum bilirubin and albumin levels significantly improved in patients with abnormal values at entry (P < .05). Virological breakthrough was detected in 13 subjects after a median of 61 weeks of lamivudine treatment and was confirmed to be caused by YMDD mutants in all patients tested. None of the patients with virological breakthrough showed a complete loss of clinical response to lamivudine. Serum ALT and bilirubin levels in patients with and without virological breakthrough were not significantly different at last study follow-up. Study results show that lamivudine is safe and effective in liver transplant recipients with recurrent hepatitis B. However, the high rate of virological breakthrough with prolonged therapy indicates the need for further studies of combination antiviral therapy in this patient population. Our results and others further establish the improving long-term outcomes with LT for patients with hepatitis B through advances in prevention of reinfection, as well as the availability of safe and effective antiviral therapies to treat patients with HBV recurrence.

AB - Hepatitis B virus (HBV) infection after liver transplantation (LT) may lead to severe and rapidly progressive graft failure. Antiviral treatment may be of benefit in selected patients with recurrent hepatitis B post-LT. The aim of this prospective open-label study is to determine the safety and efficacy of lamivudine in 33 liver transplant recipients with active HBV infection. The median time from LT to study enrollment was 51 months, all patients were hepatitis B surface antigen positive, and 75% and 94% of subjects had detectable hepatitis B e antigen (HBeAG) and HBV DNA at entry, respectively. The median duration of lamivudine treatment on study was 85 weeks, during which time median HBV DNA levels became undetectable by 16 weeks and 9% of patients lost previously detectable HBeAg. Serum alanine aminotransferase (ALT) levels improved in most patients and normalized in 27% of patients with elevated values pretreatment. Serum bilirubin and albumin levels significantly improved in patients with abnormal values at entry (P < .05). Virological breakthrough was detected in 13 subjects after a median of 61 weeks of lamivudine treatment and was confirmed to be caused by YMDD mutants in all patients tested. None of the patients with virological breakthrough showed a complete loss of clinical response to lamivudine. Serum ALT and bilirubin levels in patients with and without virological breakthrough were not significantly different at last study follow-up. Study results show that lamivudine is safe and effective in liver transplant recipients with recurrent hepatitis B. However, the high rate of virological breakthrough with prolonged therapy indicates the need for further studies of combination antiviral therapy in this patient population. Our results and others further establish the improving long-term outcomes with LT for patients with hepatitis B through advances in prevention of reinfection, as well as the availability of safe and effective antiviral therapies to treat patients with HBV recurrence.

UR - http://www.scopus.com/inward/record.url?scp=0034965224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034965224&partnerID=8YFLogxK

U2 - 10.1053/jlts.2001.24896

DO - 10.1053/jlts.2001.24896

M3 - Article

C2 - 11443577

AN - SCOPUS:0034965224

VL - 7

SP - 504

EP - 510

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 6

ER -